NSE · BLISSGVS
Bliss GVS Pharma Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹261 Cr with net profit ₹74 Cr — a 28.17% net margin, versus 17.43% the period before.
Shareholding
As of 2026-09-30
- Promoter50.07%
- Public35.28%
- FII5.03%
- DII9.62%
47,944 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 6.27× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 4. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 6.27× (₹118 to ₹739.9) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #9 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,80,675 Cr | 83.22 | 9.81 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹52,297 Cr | 45.64 | 5.05 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,333 Cr | 32.73 | 8.51 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,468 Cr | 95.31 | 19.38 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹18,431 Cr | 64.81 | 6.68 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,110 Cr | 27.22 | 5.37 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹17,122 Cr | 22.87 | 4.12 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,764 Cr | 24.59 | 4.13 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd.(this company) | ₹6,535 Cr | 40.17 | 4.97 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,347 Cr | 40.06 | 5.32 | 13.31% | 18.57% |
AI analysis
AI-generated · google/gemini-2.5-flashBliss GVS Pharma Ltd. has a market capitalization of Rs 5119 Cr. The company reported a revenue of Rs 773.53 Cr with a profit margin of 13.93%. Its PE ratio is 149.91 and EPS is 12.44. The 52-week high for the share price was Rs 553, and the 52-week low was Rs 118.
Positives
- +The debt-to-equity ratio of 0.05 is low, suggesting limited financial leverage.
- +The Return on Capital Employed (ROCE) is 16.483%, which indicates efficient use of capital.
- +The dividend yield is 20%, which may be attractive to dividend-seeking investors.
Negatives
- −The company is under LT-ASM Stage 4 surveillance, indicating increased regulatory scrutiny.
- −The promoter shareholding decreased from figures that might have been higher in previous periods, though historical data is incomplete for direct comparison.
- −Revenue growth of 5.1% could be considered moderate.
- −The PE ratio of 149.91 is higher than the EPS of 12.44, suggesting a high valuation.
Financial Performance
Bliss GVS Pharma Ltd. generated a revenue of Rs 773.53 Cr, demonstrating a revenue growth of 5.1%. The company's profit margin stood at 13.93%. Over the past year (Mar 2025 to Mar 2026), annual revenue fluctuated, with a high of Rs 211.54 Cr in Mar 2026 and a low of Rs 156 Cr in Mar 2025. Net profit also varied, reaching a high of Rs 32.42 Cr in Mar 2026 and a low of Rs 11.45 Cr in Mar 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 10.82%, while the Return on Capital Employed (ROCE) is 16.483%. The Earnings Per Share (EPS) is reported at Rs 12.44. The profit margin for the latest period is 13.93%.
Balance Sheet
Bliss GVS Pharma Ltd. has a book value of Rs 112.48. The debt-to-equity ratio is 0.05, indicating a low level of debt relative to equity.
Ownership & Pledges
As of March 31, 2026, promoter holding in Bliss GVS Pharma Ltd. was 35.3575%. FIIs held 10.4487% and DIIs held 5.0411% of the shares. Public shareholding was 49.1527%. There were no promoter shares pledged reported for the period.
Regulatory & Surveillance
Bliss GVS Pharma Ltd. is currently under LT-ASM (Additional Surveillance Measure) Stage 4. This indicates heightened monitoring by regulatory bodies due to specific criteria met by the scrip.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.